LHC Group, Inc. (LHCG) CEO Sells $645,117.90 in Stock
LHC Group, Inc. (NASDAQ:LHCG) CEO Keith G. Myers sold 6,790 shares of the company’s stock in a transaction that occurred on Monday, January 7th. The stock was sold at an average price of $95.01, for a total value of $645,117.90. Following the sale, the chief executive officer now directly owns 155,475 shares in the company, valued at $14,771,679.75. The sale was disclosed in a filing with the SEC, which is available through this link.
NASDAQ:LHCG opened at $97.61 on Friday. LHC Group, Inc. has a fifty-two week low of $58.65 and a fifty-two week high of $107.51. The firm has a market cap of $3.01 billion, a P/E ratio of 40.22, a P/E/G ratio of 1.36 and a beta of 0.88. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.61 and a current ratio of 1.61.
LHC Group (NASDAQ:LHCG) last released its quarterly earnings results on Wednesday, October 31st. The health services provider reported $0.95 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.95. The company had revenue of $507.00 million for the quarter, compared to analyst estimates of $515.03 million. LHC Group had a return on equity of 8.23% and a net margin of 3.85%. LHC Group’s quarterly revenue was up 88.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.64 EPS. Sell-side analysts forecast that LHC Group, Inc. will post 3.53 EPS for the current year.
Several research firms recently weighed in on LHCG. Bank of America set a $119.00 price target on LHC Group and gave the company a “buy” rating in a report on Tuesday, September 18th. BidaskClub upgraded LHC Group from a “buy” rating to a “strong-buy” rating in a report on Friday, September 28th. Craig Hallum lowered LHC Group from a “buy” rating to a “hold” rating and decreased their price target for the company from $99.00 to $92.00 in a report on Friday, October 26th. William Blair restated a “buy” rating on shares of LHC Group in a report on Thursday, November 1st. Finally, Robert W. Baird increased their price target on LHC Group from $95.00 to $98.00 and gave the company a “neutral” rating in a report on Friday, November 2nd. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $105.77.
LHC Group Company Profile
LHC Group, Inc, a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company operates through four segments: Home Health Services, Hospice Services, Community-Based Services, and Facility-Based Services. The Home Health Services segment offers home nursing services, including wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education; medically-oriented social services; and physical, occupational, and speech therapy services.
Further Reading: Ex-Dividend
Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.